Relevant bibliographies by topics / He52 / Dissertations / Theses
To see the other types of publications on this topic, follow the link: He52.

Dissertations / Theses on the topic 'He52'

Author: Grafiati
Published: 28 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'He52.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Waiz, Oliver [Verfasser], and Jan [Akademischer Betreuer] Harder. "Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom." Freiburg : Universität, 2012. http://d-nb.info/1123468273/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bender, Brendan. "Pharmacometric Models for Antibody Drug Conjugates and Taxanes in HER2+ and HER2- Breast Cancer." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-292617.

Full text
Abstract:
In oncology, there is a need to optimize drug treatment for efficient eradication of tumors, minimization of adverse effects (AEs), and prolonging patient survival. Pharmacometric models can be developed to streamline information between drug development phases, describe and quantify response to treatment, and determine dose regimens that balance toxicity and efficacy. In this thesis, data from trastuzumab emtansine (T-DM1) and taxane drug treatment were used to develop pharmacometric models of pharmacokinetics (PK), AEs, anti-tumor response, and survival, supporting drug development. T-DM1 is
APA, Harvard, Vancouver, ISO, and other styles
3

Aldana, Hidalgo Julio Xavier, Parodi Augusto José Amador, Palacios Jorge Martin Arredondo, et al. "Estrategias de redacción - HE59 201801." Universidad Peruana de Ciencias Aplicadas (UPC), 2018. http://hdl.handle.net/10757/624389.

Full text
Abstract:
Descripción: Estrategias de Redacción es un curso de Humanidades, que brinda al participante un conjunto de herramientas lingüísticas para la redacción en el entorno laboral, tales como el uso apropiado de la normativa del español y la aplicación de estrategias de redacción como la enumerativa y la causal. Estas últimas se emplean en la elaboración de un tipo de documento: el informe de recomendación. Propósito: El curso desarrolla la competencia de comunicación escrita en el primer nivel de logro. La asignatura se orienta a la redacción de textos administrativos que ayuden a optimizar el
APA, Harvard, Vancouver, ISO, and other styles
4

Li, Bob T. "Targeting HER2 in lung cancers." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/23996.

Full text
Abstract:
Therapeutic targeting of human epidermal growth factor receptor 2 (HER2) has transformed the care of women with breast cancers with substantial improvement in survival. In contrast, lung cancers remain the leading cause of cancer mortality, with over 1.7 million deaths annually worldwide. This research set out to test whether the therapeutic advances in targeting HER2 in breast cancers may be applied to lung cancers to improve outcomes. Translational research on lung tumour biospecimens from 175 patients found that HER2 mutations and HER2 amplification are two distinct therapeutic targets, eac
APA, Harvard, Vancouver, ISO, and other styles
5

(UPC), Universidad Peruana de Ciencias Aplicadas, and Celis Ingunza Sandy Cecilia. "Creatividad Y Liderazgo-HE50-201601." Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639326.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de negocios e Ingeniería y que desarrolla una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a los vertiginosos cambios tecnológicos y sociales que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. Esto enfrenta a los ejecutivos a cada vez mayores exigencias profes
APA, Harvard, Vancouver, ISO, and other styles
6

(UPC), Universidad Peruana de Ciencias Aplicadas, and Garcia Soria Juddy Grethel Nora. "Creatividad Y Liderazgo-HE50-201602." Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639327.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de negocios e Ingeniería y que desarrolla una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a los vertiginosos cambios tecnológicos y sociales que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. Esto enfrenta a los ejecutivos a cada vez mayores exigencias profes
APA, Harvard, Vancouver, ISO, and other styles
7

(UPC), Universidad Peruana de Ciencias Aplicadas, and Ilizarbe Jurado Anndy Antonio. "Creatividad Y Liderazgo-HE50-201701." Universidad Peruana de Ciencias Aplicadas (UPC), 2017. http://hdl.handle.net/10757/639328.

Full text
Abstract:
Creatividad y Liderazgo es un curso de formación general de carácter teórico y práctico que está dirigido a estudiantes de quinto ciclo a más de las Facultades de Negocios e Ingeniería y busca desarrollar una de las competencias generales de nuestro modelo educativo: Pensamiento Innovador.El curso Creatividad y Liderazgo surge como una respuesta a la necesidad de profesionales que cuenten con estrategias y metodologías para afrontar los vertiginosos cambios que ocurren en nuestros días los que a su vez producen profundas transformaciones en la cultura corporativa de empresas e instituciones. E
APA, Harvard, Vancouver, ISO, and other styles
8

Collins, Bridget. "Vaccination with Her2/neu peptides elicits an endogenous anti-Her2/neu antibody response in mice." [New Haven, Conn. : s.n.], 2007. http://ymtdl.med.yale.edu/theses/available/etd-08062007-143035/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vicario, Rocío. "Immunotherapy against HER2-positive breast cancers." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/400279.

Full text
Abstract:
El 20% de los tumores mamarios sobre expresan el receptor de tirosina quinasa HER2, debido a su amplificación génica, tanto dentro de los cromosomas (HSR) como fuera ellos (DM). Se sabe muy poco acerca de la respuesta clínica o el rol en resistencia a terapias de estos patrones de amplificación. Por otro lado, un porcentaje de pacientes HER2+ expresa fragmentos carboxyl-terminales de HER2, p95HER2. Mas de la mitad de pacientes HER2+ no responde a las terapias disponibles. Hasta el momento, se desconoce si p95HER2 puede ser un blanco terapéutico. En este trabajo estudiaremos resistencia
APA, Harvard, Vancouver, ISO, and other styles
10

Maslak, Kerstin [Verfasser]. "Untersuchung zur synergistischen Wirkung von Lapatinib (GW 2016), einem potenten dualen HER1-HER2-Tyrosinkinaseinhibitor, und Fulvestrant, einem Östrogenrezeptorantagonisten, in HER2 und nicht HER2 überexprimierenden Brustkrebszellen / Kerstin Maslak." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2012. http://d-nb.info/1030290946/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Barros, Fabrício Félix Tabuada. "Biological characterisation of HER2 amplified breast cancer." Thesis, University of Nottingham, 2013. http://eprints.nottingham.ac.uk/13134/.

Full text
Abstract:
Breast carcinoma is the most frequent type of cancer affecting women. Among the recently described molecular and phenotypic classes of breast cancer, human epidermal growth factor receptor 2 (HER2)-positive tumours are associated with a poor prognosis. HER2 status is currently assessed in routine breast cancer reporting using immunohistochemistry (IHC) in addition to in situ hybridisation (ISH) in borderline cases. The ability of HER2 gene status to predict response to targeted therapy (Trastuzumab) is well documented. However, prognostic information provided by IHC expression categories and p
APA, Harvard, Vancouver, ISO, and other styles
12

Frutuoso, José Amaro de Oliveira. "Estudo de HER2 em carcinomas da mama." Master's thesis, Universidade de Aveiro, 2010. http://hdl.handle.net/10773/8790.

Full text
Abstract:
Mestrado em Biologia Molecular e Celular<br>O receptor tipo 2 do factor de crescimento epidérmico humano (HER2 - Human Epidermal growth factor Receptor-type 2) é um importante marcador tumoral na caracterização do cancro da mama, contudo existe controvérsia relativamente ao modo como se avalia o seu estado. A primeira avaliação é efectuada por método imunocitoquímico, determinando a sobre-expressão da proteína HER2. Os casos equívocos requerem estudo molecular por hibridação in situ, determinando o estado do gene HER2. O presente estudo avalia a concordância entre a amplificação do g
APA, Harvard, Vancouver, ISO, and other styles
13

Ashok, Mahima. "Analysis of HER2 testing in breast cancer." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/29711.

Full text
Abstract:
Thesis (Ph.D)--Biomedical Engineering, Georgia Institute of Technology, 2010.<br>Committee Chair: Griffin, Paul; Committee Member: Butera, Robert; Committee Member: Halpern, Michael; Committee Member: Nichols, Richard; Committee Member: Vidakovic, Brani. Part of the SMARTech Electronic Thesis and Dissertation Collection.
APA, Harvard, Vancouver, ISO, and other styles
14

MAFFEIS, VALERIA. "VALUTAZIONE DI HER2 NEL CARCINOMA SIEROSO ENDOMETRIALE." Doctoral thesis, Università degli studi di Padova, 2022. http://hdl.handle.net/11577/3459384.

Full text
Abstract:
BACKGROUND: Uterine serous carcinoma (USC) is an aggressive tumor, responsible for approximately half of endometrial carcinoma-related mortality. A subset of USC shows HER2 overexpression due to ERBB2 amplification, and a recent phase 2 trial demonstrated that these patients benefit from treatment with trastuzumab. Therefore, accurate assessment of HER2 status is critical to properly select patients for targeted therapy. However, previous work has shown a significant intratumoral heterogeneity of ERBB2 amplification in USC and Next Generation Sequencing (NGS) is (and will be) increasingly used
APA, Harvard, Vancouver, ISO, and other styles
15

Kawamoto, Megumi. "HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo." Kyoto University, 2013. http://hdl.handle.net/2433/180345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Thomas, Gaëlle. "Ciblage de l'entité HER2/HER3 par des anticorps monoclonaux pour le traitement des cancers du pancréas exprimant faiblement HER2." Thesis, Montpellier 1, 2013. http://www.theses.fr/2013MON1T011.

Full text
Abstract:
Avec un taux de survie à 5 ans inférieur à 5%, l'adénocarcinome pancréatique (PDAC) est l'un des cancers les plus agressifs et pour lequel les thérapies existantes sont largement insuffisantes. Ce cancer est caractérisé par un tissu fibreux dense et un stroma très développé, en constante interaction avec la tumeur, favorisant le développement d'un environnement propice à la progression tumorale. Actuellement, la gemcitabine est la seule chimiothérapie approuvée capable de prolonger légèrement la survie des patients. Une thérapie ciblée dirigée contre l'EGFR, l'erlotinib, a prouvé que le ciblag
APA, Harvard, Vancouver, ISO, and other styles
17

Palomeras, Sònia. "DNA methylome in HER2-positive resistant breast cancer." Doctoral thesis, Universitat de Girona, 2019. http://hdl.handle.net/10803/667582.

Full text
Abstract:
The major clinical problem for HER2+ breast cancer target therapies is the acquisition of resistance. The DNA methylation status of the promoter gene region has been described as a common epigenetic alteration for transcriptional repression in human malignancies as breast cancer. The purpose of this thesis was to evaluate how the DNA methylation was involved in trastuzumab and lapatinib resistance in HER2+ breast cancer. We identify the epigenetic silencing of the TGFBI gene in trastuzumab resistance HER2+ breast cancer cell model and in post-treatment samples of patients treated with neoadjuv
APA, Harvard, Vancouver, ISO, and other styles
18

Bonsignore, Lynne Alis Jean. "Cardiovascular function in HER2-postivie breast cancer survivors." Thesis, University of British Columbia, 2014. http://hdl.handle.net/2429/50924.

Full text
Abstract:
Background: Trastuzumab, a HER2 antagonist, has been shown to improve rates of overall survival in patients with HER2-positive breast cancer. However, cardiotoxic effects associated with treatment limits these benefits. Due to an increase in survival years, women with a history of HER2-positive breast cancer might be at increased risk of developing cardiotoxicity (i.e., LVEF < 55% with or without accompanying symptoms of heart failure) during survivorship. Exercise (“stress”) conditions is an established method to examine comprehensively impairments in cardiovascular function that may go undet
APA, Harvard, Vancouver, ISO, and other styles
19

Su, Vi-Minh-Tri. "The role of Grb2 in HER2-mediates tumourigenesis." Thesis, McGill University, 2012. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=110360.

Full text
Abstract:
Grb2, an adaptor protein, is ubiquitously expressed and is involved in mediating a multitude of cellular processes in various body tissues such as development and tumourigenesis. Grb2 binds to proteins via its Src-homology domains and by doing so brings them in proximity of each other. In breast tissue, Grb2 can recruit SOS and Gab1 to the plasma membrane by binding to a specific phosphorylated tyrosine residue of HER2, a member of the epidermal growth factor receptor family. HER2 is overexpressed and activated in 20-30% of human breast cancers and correlates with poor patient prognosis. In tr
APA, Harvard, Vancouver, ISO, and other styles
20

Magub, Stephanie Jane. "The role of HER2 in canine mammary cancer." Thesis, University of Kent, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.580400.

Full text
Abstract:
While the role of the EGF family (in particular the HER2 receptor) has been well documented in human cancers, its role in the progression of canine mammary cancer is less well understood. Dogs have long been used as models of human disease in the development of human therapeutics, however the animal health market is only just beginning to develop animal-specific therapies. This project aimed to survey the expression of the complete family of EGF receptors and ligands in a range of normal tissues, and also in benign and malignant canine mammary cancers. In addition to this, the functional role
APA, Harvard, Vancouver, ISO, and other styles
21

Wang, Yan. "Peptide-drug conjugate for Her2-targeted drug delivery." Scholarly Commons, 2018. https://scholarlycommons.pacific.edu/uop_etds/3567.

Full text
Abstract:
Recent strategies for anticancer drug design have been focused on utilizing antibody as a drug or targeted moiety for targeted drug delivery. Antibody−drug conjugates (ADCs) have become a promising new class of targeted therapeutic agents for treatment of cancer. ADCs are designed to preferentially direct a cytotoxic drug to a cell-surface antigen recognized by an antibody. However, there are some challenges in developing ADCs, such as limited solid tumor penetration, high manufacturing costs and antibody-drug stoichiometry. Smaller molecules such as peptides have been shown to specifically bi
APA, Harvard, Vancouver, ISO, and other styles
22

Silva, Maria João da Costa Soares da. "Clinical and molecular characterization of feline mammary carcinomas overexpressing HER2 proto-oncogene (FMC-HER2+) : new strategies for effective diagnostic and cancer therapy." Doctoral thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2016. http://hdl.handle.net/10400.5/12008.

Full text
Abstract:
Tese de Doutoramento em Ciências Veterinárias na Especialidade de Ciências Biológicas e Biomédicas<br>mariajosoares@gmail.com<br>Considering the scarce data available in feline mammary carcinoma (FMC) and despite its importance in veterinary clinical practice, this thesis emerges in order to increase the knowledge of this tumor type, especially the FMC-HER2 positive. In the first two studies, the protocols for detection and quantification of the fHER2 and Ki-67 biomarkers were optimized and validated. These studies demonstrated that, in cats, the incidence of fHER2 overexpression were similar
APA, Harvard, Vancouver, ISO, and other styles
23

VITALE, STEFANIA. "Role of endocrine therapy in combination with anti-HER2 therapy and CDK4/6 inhibitors in hormone receptor positive/HER2 positive breast cancer." Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1073185.

Full text
Abstract:
In clinical practice, patients with advanced ER+/HER2+ BC are treated with a combination of anti-HER2 and chemotherapy as first choice but it is clear that a proportion of these derive prolonged benefit from the combination of hormonal therapy (HT) and anti-HER2 therapy (AH2T). Preclinical evidence from cellular models of BC indicates that ER and HER2 pathways are strictly interdependent and that targeting both pathways in ER+/HER2+ BC might be an effective therapeutic strategy; few trials investigated this combination showing a significant, albeit modest, clinical improvement. CDK4/6 pathway
APA, Harvard, Vancouver, ISO, and other styles
24

Pimentel, Franklin Fernandes. "Superexpressão simultânea das proteínas HER2 e WIPF2 no câncer de mama." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/17/17145/tde-14072015-171556/.

Full text
Abstract:
Introdução: o câncer de mama que apresenta amplificação/superexpressão do HER2 apresenta-se com pior prognóstico e seu amplicon se localiza no locus 17q12-q21. O gene WIPF2, relacionado a motilidade celular, localiza-se no mesmo locus e também se encontra presente no amplicon do HER2. Objetivo: avaliar a superexpressão simultânea do HER2 e WIPF2 através de marcação imunohistoquímica. Métodos: foram selecionados 94 casos de carcinoma ductal invasor de mama, sendo possível a obtenção de material em 87. Foi realizada técnica de microarranjo tecidual e as lâminas foram analisadas. Informações clín
APA, Harvard, Vancouver, ISO, and other styles
25

Horsten, Hans Henning von. "HE2, ein humanes Spermienoberflächenantigen epididymaler Herkunft." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=965260402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

McCurry, Dustin. "Tumor Associated Antigens Harbor Readily Defined and Universally Immunogenic Regions Relevant For Cancer Immunotherapy." Thesis, The University of Arizona, 2017. http://hdl.handle.net/10150/623490.

Full text
Abstract:
A Thesis submitted to The University of Arizona College of Medicine - Phoenix in partial fulfillment of the requirements for the Degree of Doctor of Medicine.<br>Recent advances in cancer immunology, highlighted by immune checkpoint inhibitors, have demonstrated that immunotherapy is a viable option in the oncologist’s armamentarium. Despite these advances, many patients are nonresponders. Preliminary studies have suggested that non-responders lack a de-novo anti-tumor antigen immune response that can be unmasked by checkpoint blockade; thus, strategies to induce anti-tumor immune responses ar
APA, Harvard, Vancouver, ISO, and other styles
27

Al-Zahrani, Khalid. "The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis." Thesis, Université d'Ottawa / University of Ottawa, 2018. http://hdl.handle.net/10393/38614.

Full text
Abstract:
Over the past two decades, the mammalian Ste20-like kinase (SLK) has been characterized for its role in regulating cellular migration, proliferation and apoptosis in fibroblasts and myoblasts. In mammary epithelial cells, SLK has been shown to be required for efficient epithelial-to-mesenchymal transition and to be activated downstream of the HER2/Neu-oncogene to control chemotactic cellular migration. Here, we assessed the role of SLK in HER2/Neu-induced mammary tumorigenesis in vivo. As SLK is activated downstream of HER2/Neu, we hypothesized that the loss of SLK would significantly delay tu
APA, Harvard, Vancouver, ISO, and other styles
28

Davide, Angelini Pier. "her2 hyper-activation through the production of carboxy-terminal fragments." Doctoral thesis, Universitat Autònoma de Barcelona, 2014. http://hdl.handle.net/10803/133269.

Full text
Abstract:
INTRODUCCIÓ: Diversos tipus dʼestrès, incloent oncògens actius i dany al DNA, són capaços de induir una aturada irreversible del cicle cel·lular que es defineix com senescència prematura [93-103]. En clínica, els tractaments que actuen produint dany al DNA indueixen apoptosi o bé sensència prematura, disminuint la progressió tumoral [217]. Tot i la resposta inicial, la senescència induïda pel tractament pot suposar un empitjorament de la resposta clínica a llarg termini. De fet, sota tractament, les cèl·lules cancerígenes senescents augmenten la ratio de recaiguda a través del Fenotip S
APA, Harvard, Vancouver, ISO, and other styles
29

Zhang, Junjie. "Mechanisms of resistance toT-DM1 in HER2-positive breast cancer." Doctoral thesis, Universitat Autònoma de Barcelona, 2018. http://hdl.handle.net/10803/650489.

Full text
Abstract:
El cáncer de mama HER2-positivo representa alrededor del 15-30% del total de pacientes con cáncer de mama. Este subtipo tiene un mal pronóstico, seguido del subtipo Triple-negativo (TNBC), que lo tiene aún peor. Actualmente, varios medicamentos están aprobados para las pacientes HER2-positivo, como Trastuzumab, Lapatinib y T-DM1. Sin embargo, a menudo éstas adquieren resistencia a estas terapias en un período de 1 a 2 años. El objetivo principal de este estudio es definir los mecanismos de resistencia a T-DM1. Durante mi tesis, generé líneas celulares resistentes a T-DM1 y exploré diferentes p
APA, Harvard, Vancouver, ISO, and other styles
30

Weitsch, Karl Georg. "HER2-neu-Expression und -Genamplifikation in muskelinvasiven Urothelkarzinomen der Harnblase." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=976305666.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Kornmeier, Anke. "HER2 und Topoisomerase IIa-Expression und Amplifikation des Mamma-Karzinoms." Diss., lmu, 2008. http://nbn-resolving.de/urn:nbn:de:bvb:19-87668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Lo, Vivian. "The Role of Periostin in HER2/ErbB2-induced Breast Cancer." Thèse, Université d'Ottawa / University of Ottawa, 2011. http://hdl.handle.net/10393/19909.

Full text
Abstract:
Periostin (Postn) is a secreted cell adhesion protein that shares a structural homology to the insect axon guidance protein fasciclin I (FAS1). Periostin interacts with multiple cell-surface receptors, most notably integrins, which activate signaling pathways to promote cancer cell survival, angiogenesis, invasion, and metastasis. Interestingly, periostin is frequently overexpressed in numerous human cancers, including breast, lung, colon, pancreatic, and ovarian cancer. Here, we investigated the role of periostin in HER2/ErbB2-induced mammary tumorigenesis. Although periostin is primarily exp
APA, Harvard, Vancouver, ISO, and other styles
33

Leung, Wing Yin. "Response and resistance to lapatinib in HER2-overexpressing breast cancer." Thesis, University of Oxford, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.669708.

Full text
Abstract:
HER2 overexpression has been implicated in breast cancer. Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in advanced HER2-positive breast cancer patients who have previously progressed on trastuzumab treatment. Recent meta-analysis of several clinical trials showed that lapatinib was inferior to trastuzumab as a neoadjuvant treatment combined with chemotherapy; however, the mechanism underlying this difference remains unclear. This thesis aimed to assess the acute response and mechanism of resistance to lapatinib in HER2-overexpressing breast cancer cell lines SK-BR-3 and BT-474.
APA, Harvard, Vancouver, ISO, and other styles
34

Lella, Divya Jyothi. "Functionalization and Modification of Naphthaquinone Analogs as HER2 Kinase Inhibitors." TopSCHOLAR®, 2014. http://digitalcommons.wku.edu/theses/1325.

Full text
Abstract:
HER2 overexpression in breast cancer tumors predicts lower overall survival. Because of the aggressive nature of HER2 tumors and the association with metastatic disease, the HER2 receptor holds great promise as a therapeutic target in metastatic breast cancer. We are developing small molecule inhibitors that bind to the ATP binding site of the tyrosine kinase domain in order to inhibit tyrosine auto-phosphorylation. This process controls biological pathways that mediate the cell growth. In normal cells this process is highly controlled. We are targeting the modification of the side chain of th
APA, Harvard, Vancouver, ISO, and other styles
35

Saito, Hiroko. "Rôle des protéines PDZ dans la fonction de ERBB2/HER2." Aix-Marseille 2, 2002. http://www.theses.fr/2002AIX22015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Kataoka, Yoshiki. "HER2 expression and its clinicopathological features in resectable gastric cancer." Kyoto University, 2013. http://hdl.handle.net/2433/174804.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Carli, Diego Michelon de. "EXPRESSÃO IMUNOISTOQUÍMICA DE HER2 EM ADENOCARCINOMA DO ESTÔMAGO NA REGIÃO CENTRAL DO RIO GRANDE DO SUL." Universidade Federal de Santa Maria, 2013. http://repositorio.ufsm.br/handle/1/5825.

Full text
Abstract:
Introduction: Worldwide, Gastric Cancer (GC) is the fourth cancer in incidence and the second most common cause of cancer death. Because it is asymptomatic in the early stages, it is often diagnosed in advanced stages. HER2 gene expression has been identified in about 20% of GC. Its expression is associated with a worse prognosis for GC patients. Objectives: To study HER2 immunoexpression in specimens of gastric adenocarcinoma and its association with histological classification and anatomical location. Patients and methods: We conduct a cross-sectional study, where we analyzed HER2 immunoexpr
APA, Harvard, Vancouver, ISO, and other styles
38

Siekiera, Wolfgang. "Charateristika von Patientinnen mit Hirnmetastasen beim HER2/neu- überexprimierenden, metastasierten Mammakarzinom." Diss., lmu, 2006. http://nbn-resolving.de/urn:nbn:de:bvb:19-59355.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Hüsemann, Yves. "Untersuchung der systemischen Tumorprogression des Mammakarzinoms anhand Her2/neu-transgener Mäuse." Diss., lmu, 2008. http://nbn-resolving.de/urn:nbn:de:bvb:19-86688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Rongcun, Yang. "The HER2/neu oncoprotein and dendritic cells in immunity against tumors /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4052-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Docherty, Fiona Margaret. "The role of HEY2 in pluripotency of human embryonic stem cells." Thesis, University of Cambridge, 2015. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Hendriks, Bart S. (Bart Sebastian) 1976. "EGFR & HER2 trafficking and signaling dynamics : experimental and modeling studies." Thesis, Massachusetts Institute of Technology, 2003. http://hdl.handle.net/1721.1/17009.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2003.<br>Includes bibliographical references.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>EGFR and HER2 expression levels have distinguished themselves as important factors in contributing to various types of cancers including breast and ovarian cancers, but quantitative linkages between receptor expression levels and aberrant cell behaviors are not well understood. The ability to interpret and predic
APA, Harvard, Vancouver, ISO, and other styles
43

Westerberg, Cornelia. "Development of an Affibody-based Prodrug Against HER2 for Cancer Therapy." Thesis, KTH, Proteinvetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-302213.

Full text
Abstract:
Affinity proteins constitute an important category of cancer therapeutics. Owing to properties such as high target affinity and selectivity, therapeutic proteins offer more targeted therapy than small molecule drugs. The target molecules are typically proteins that are overexpressed on the surface of tumour cells, such as membrane-bound receptors. However, these surface proteins are usually expressed in normal tissues as well, resulting in on-target off-tumour toxicity. Proteins with a higher tissue selectivity are thus needed. Here, this has been addressed by developing prodrug proteins depen
APA, Harvard, Vancouver, ISO, and other styles
44

Pinto, Daniela Amaral Tavares. "Polimorfismo no gene HER2 no cancro da mama e do ovário." Master's thesis, Universidade do Porto. Reitoria, 2003. http://hdl.handle.net/10216/9808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Fuku, Xolile Godfrey. "Quantum dots genosensor for Her2/Neu oncogene - a breast cancer biomarker." University of the Western Cape, 2014. http://hdl.handle.net/11394/4331.

Full text
Abstract:
Philosophiae Doctor - PhD<br>The human epidermal growth factor receptor (HER)-family of receptor tyrosine kinases; human epidermal growth factor receptor 1, human epidermal growth factor receptor 2, human epidermal growth factor receptor 3 and human epidermal growth factor receptor 4 (EGFR/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4) plays a major role in the pathogenesis of many solid tumours, in approximately 25 - 30% of breast cancers. Breast cancer is the second most common type of cancer and affects around 3000 women annually in South Africa alone. While the benefits of treatment and can
APA, Harvard, Vancouver, ISO, and other styles
46

Pinto, Daniela Amaral Tavares. "Polimorfismo no gene HER2 no cancro da mama e do ovário." Dissertação, Universidade do Porto. Reitoria, 2003. http://hdl.handle.net/10216/9808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Khoshaba, Ramina. "PROMOTING ROLE OF AKR1B10 IN HER2+ BREAST CANCER AT EARLY STAGE." OpenSIUC, 2019. https://opensiuc.lib.siu.edu/dissertations/1678.

Full text
Abstract:
Breast cancer is the most common type of cancer diagnosed among women in the United States, and the second cause of female cancer-related death, with approximately 40,000 deaths annually. Aldo-keto reductase 1B10 (AKR1B10) is a 35-kDa protein that is highly expressed in breast cancer in infiltrative and Ductal Carcinoma in Situ (DCIS) stages. Recent studies have demonstrated that AKR1B10 promotes breast cancer cell adhesion and invasion through the expression of integrin α5 and δ-catenin. Human epidermal growth factor receptor2 (HER2) is a tyrosine kinase receptor which is over expressed in ov
APA, Harvard, Vancouver, ISO, and other styles
48

Palladini, Arianna <1978&gt. "Therapeutic strategies to overcome tumor heterogeneity in HER2 positive mammary carcinoma." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9857/1/Palladini_Arianna_tesi.pdf.

Full text
Abstract:
Target therapy has significantly improved the management and the outcome of different types of tumors, including HER2-positive breast cancers. Nevertheless, overall, target therapy has also shown several limitations over the years, as demonstrated by the significant rate of patients who developed resistance to therapy. This is also true for the monoclonal antibody trastuzumab, the gold standard therapy against HER2-positive breast cancer. Tumor heterogeneity is a key factor in resistance to target therapy. This heterogeneity can be intended as spatial, both within a single tumor and among mul
APA, Harvard, Vancouver, ISO, and other styles
49

OMARINI, Claudia. "PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​." Doctoral thesis, Università degli studi di Modena e Reggio Emilia, 2020. http://hdl.handle.net/11380/1201013.

Full text
Abstract:
Background I tumori mammari con amplificazione o overespressione del gene Human Epidermal growth factor Receptor 2 (HER2) costituiscono circa il 20% delle diagnosi di tumori mammari. Tali tumori sono caratterizzati da una biologia particolarmente aggressiva e da prognosi infausta. Nelle pazienti con tumore mammario HER2 positivo, diagnosticato in stadio precoce, la chemioterapia neoadiuvante rimane una ottima opzione di trattamento, in quanto la risposta alla terapia correla significativamente con la sopravvivenza. In particolare, l’ottenimento della risposta patologica completa (pCR) è indic
APA, Harvard, Vancouver, ISO, and other styles
50

Kawaguchi, Kousuke. "Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity." Kyoto University, 2018. http://hdl.handle.net/2433/231002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'He52' for other source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography